바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.63 No.2
Citation Share

Comparison of Immunohistochemical Expression of CBP(cAMP-responsive Element Binding Protein Transcriptional Co-activator between Premalignant Lesions and Squamous Cell Carcinomas in the Lungs

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2007, v.63 no.2, pp.165-172



& (2007). Comparison of Immunohistochemical Expression of CBP(cAMP-responsive Element Binding Protein Transcriptional Co-activator between Premalignant Lesions and Squamous Cell Carcinomas in the Lungs. Tuberculosis & Respiratory Diseases, 63(2), 165-172.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: The pathogenesis of lung cancer includes the accumulation of multiple genetic abnormalities. The CREB-binding protein(CBP) is one of several transcriptional co-activators among various sequence-specific DNA-binding transcription factors. CBP is involved in a wide range of cellular activities, such as DNA repair, cell growth, differentiation, and apoptosis that are suspected of contributing to tumorigenesis. The goal of this study was to evaluate CBP expression in a series of human lung tissues containing normal epithelium, premalignant lesions(hyperplasia and dysplasia) and squamous cell carcinomas. Materials and Methods: Immunohistochemical staining was performed on formalin-fixed paraffin-embedded sections by use of a monoclonal anti-CBP antibody. CBP expression was compared in samples from 120 patients with premalignant and malignant histological types including 20 metaplastic specimens, 40 dysplastic specimens, and 60 squamous cell carcinomas in the lung. Results: CBP expression was seen in 35% (7/20) of the metaplastic specimens. 65% (26/40) of the dysplastic specimens, and 70% (42/60) of the squamous cell carcinomas (p<0.05). According to celluar atypism, CBP expression was 50% (10/20) of the low-grade dysplastic specimens and 80% (16/20) of the high-grade dysplastic specimens(p <0.01). By cellular differentiation, CBP expression was seen in 95% (19/20) of the well differentiated squamous cell carcinomas, 85% (17/20) of the moderately differentiated carcinomas and 30% (6/20) of the poorly differentiated lesions (p <0.05). Conclusion: These results suggest that CBP may have an important role in malignant transformation of precancerous lung lesions and may be a marker for malignancy. (Tuberc Respir Dis 2007; 63: 165-172)

keywords
CBP, Lung, Metaplasia, Dysplasia, Squamous cell carcinoma., CBP, Lung, Metaplasia, Dysplasia, Squamous cell carcinoma.

Reference

1.

(2005) Chapter 16, Molecular techniques of early detection of lung cancer and for studying preneoplasia, Philadelphia, PA: Lippincott Williams & Wilkins

2.

(1998) The promise of cancer genetics,

3.

(1997) Antiangiogenesis for cancer therapy,

4.

(1996) Targeting signal transduction for disease therapy,

5.

(1997) Human cancer syndromes: clues to the origin and nature of cancer,

6.

Control of transcription factors by signal transduction pathways: the beginning of the end,

7.

Distinct activation domains within cAMP response element-binding protein,

8.

(1995) Transcription factors responsive to cAMP,

9.

(2001) CREB-binding protein and p300 in transcriptional regulation,

10.

(1998) Signal-specific co-activator domain requirements for Pit-1 activation,

11.

(1999) p300 and CBP: partners for life and death,

12.

(2001) p300/CBP/p53 interaction and regulation of the p53 response,

13.

(2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2,

14.

(1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain,

15.

(1997) Recruitment of p300/CBP in p53-dependent signal pathways,

16.

(1997) Synergistic activation of transcription by CBP and p53,

17.

(1997) Binding and modulation of p53 by p300/CBP coactivators,

18.

(2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1,

19.

(1996) The translocation t(8;16)(p11;p13) of acute myelogenous leukemia fuses a putative acetyltransferase to the CREB-binding protein,

20.

Rowley JD, (1997) All patients with the T(11;16) (q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders,

21.

Sobulo OM, (1997) MLL is fused to CBP, a histoneacetyl transferase, intherapy-related acutemyeloid leukemia with a t(11;16)(q23;p13.3),

22.

Kitabayashi I, (1998) Interaction and functional cooperation of the leukemia- associated factors AML1 and p300 in myeloid cell differentiation,

23.

Huang S, (1999) p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein,

24.

Arias J, (nature1994;370) Activation of cAMP an mitogen responsive genes relies on a common nuclear factor,

25.

Bannister AJ, (1995) Stimulation of c-Jun activity by CBP c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro,

26.

Bannister AJ, (1995) CBP-induced stimulation of c-Fos activity is abrogated by E1A,

27.

Dai P, (1996) CBP as a transcriptional coactivator of c-Myb,

28.

Trouche D, (1996) The CBP co- activator stimulates E2F1/DP1 activity,

29.

Krecicki T, (1999) Immunohistochemically stained markers (p53, PCNA, bcl-2) in dysplastic lesions of the larynx,

30.

Karamouzis MV, (2002) Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis,

31.

Goodman RH, (2000) CBP/p300 in cell growth, transformation and development,

32.

Kishimoto M, (2005) Mutations and deletions of the CBP gene in human lung cancer,

33.

Adcock IM, (2005) Histone deacetylation: an important mechanism in inflammatory lung diseases,

34.

(2007) Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB,

35.

(2002) Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy